Originally published In Press as doi:10.1074/jbc.M112305200 on May 2, 2002
J. Biol. Chem., Vol. 277, Issue 28, 25823-25830, July 12, 2002
Nitric Oxide Ameliorates Hydrophobic Bile Acid-induced Apoptosis
in Isolated Rat Hepatocytes by Non-mitochondrial Pathways*
Eric
Gumpricht,
Rolf
Dahl,
Baruch
Yerushalmi,
Michael W.
Devereaux, and
Ronald J.
Sokol
From the Pediatric Liver Center and Liver Transplantation
Program, Section of Pediatric Gastroenterology, Hepatology, and
Nutrition, Department of Pediatrics, University of Colorado School of
Medicine, Denver, Colorado 80262 and The Children's Hospital,
Denver, Colorado 80218
Received for publication, December 21, 2001, and in revised form, April 6, 2002
 |
ABSTRACT |
Hydrophobic bile acids are toxic to isolated rat
hepatocytes by mechanisms involving mitochondrial dysfunction and
oxidative stress. In the current study we examined the role of nitric
oxide (NO), a potential mediator of apoptosis, during bile acid-induced apoptosis. Freshly isolated rat hepatocytes and hepatic mitochondria generated NO and peroxynitrite (ONOO
) in a
concentration- and time-dependent manner when exposed to the toxic bile salt glycochenodeoxycholate (GCDC) (25-500
µM), which was prevented by the nitric-oxide synthase
(NOS) inhibitors NG-monomethyl-N-arginine monoacetate
(L-NMMA) and 1400W. Relationships between hepatocyte NO
production and apoptosis were examined by comparing the effects of NOS
inhibitors with other inhibitors of GCDC-induced apoptosis. Inhibitors
of caspases 8 and 9, the mitochondrial permeability transition blocker
cyclosporin A, and the antioxidant idebenone reduced NO generation and
apoptosis in GCDC-treated hepatocytes. In contrast, NOS inhibitors had
no effect on GCDC-induced apoptosis despite marked reduction of NO and
ONOO
. However, treatment with the NO donors
S-nitroso-N-acetylpenicillamine and spermine
NONOate
[N-(-aminoethyl)N-(2-hydroxy-2-nitrohydrazino)-1,2-ethylenediamine) inhibited apoptosis and caspase 3 activity while significantly elevating NO levels above GCDC-stimulated levels. Neither NO donors nor
NOS inhibitors affected GCDC-induced mitochondrial permeability transition or cytochrome c release from liver mitochondria
or GCDC-induced mitochondrial depolarization from isolated hepatocytes, suggesting that NO inhibits bile acid-induced hepatocyte apoptosis by a
non-mitochondrial-dependent pathway. In conclusion, whereas NO produced from GCDC-treated hepatocytes neither mediates nor protects
against bile acid-induced apoptosis, higher levels of NO inhibit
GCDC-induced hepatocyte apoptosis by caspase-dependent pathways.
 |
INTRODUCTION |
The accumulation and toxicity of hydrophobic bile acids within the
liver play an important role in the pathogenesis of cholestatic liver
disorders and congenital defects in bile acid synthesis and transport
(1). Although the mechanisms responsible for bile acid-induced
hepatotoxicity have not been fully elucidated, exposure of freshly
isolated or primary cultured hepatocytes to high concentrations (500 µM--1 mM) of hydrophobic bile acids leads to
hepatocyte necrosis (2, 3), whereas exposure to lower concentrations
(25-100 µM) induces the morphologic and biochemical features of apoptosis (4, 5). Although the induction and execution of
bile acid-induced hepatocyte apoptosis may involve a variety of cell
signaling pathways, it is clear that oxidative stress and mitochondrial
perturbations are two critical steps in this apoptosis model. Several
laboratories demonstrated that hydrophobic bile acids directly
stimulate generation of reactive oxygen species
(ROS)1 from hepatocytes (2,
6) and liver mitochondria (2, 7) and that inhibition by antioxidants
protects hepatocytes from cell necrosis and apoptosis. Recent
attention has also focused on the role of the mitochondrial
permeability transition (MPT) during apoptosis. Induction of the MPT,
characterized by large amplitude swelling and loss of the
electrochemical potential across the inner mitochondrial membrane (8,
9), leads to release of cytochrome c and apoptosis-inducing
factor into cytosol, activating downstream caspases and cellular
apoptosis (10). The role of the MPT in bile acid-induced hepatocyte
necrosis and apoptosis has recently been established (11-15). Evidence
from several laboratories indicates that stimulation of the MPT by bile
acids is commensurate with increased generation of ROS (7, 11, 14, 15)
and that oxidative modification of the MPT pore may mediate its opening (16).
Recently, nitric oxide (NO) has emerged as a regulatory molecule
involved in control of a variety of biological processes. Enzymatically
produced by constitutive and inducible forms of NO synthases (NOS), NO
is found in a variety of cell types (for reviews, see Refs. 17 and 18).
In addition to its role as a cell signaling agent, NO functions as an
antioxidant by reacting with other free radical species, such as
superoxide, in a diffusion-controlled reaction yielding the potent
oxidizing and nitrating peroxynitrite (ONOO
). Therefore,
NO can operationally function as either a prooxidant or antioxidant.
Most toxicity studies in rat hepatocytes support a potent protective
effect of NO, particularly against cell death by apoptotic pathways
(19). Of particular relevance are recent reports demonstrating that NO,
administered exogenously or stimulated endogenously via NOS induction,
inhibits tumor necrosis factor-
or Fas-dependent
hepatocyte apoptosis (19-22). Several mechanisms have been proposed to
explain the anti-apoptotic effects of NO including increased cGMP
production, nitrosylation of caspases, inhibition of Bid cleavage and
translocation to mitochondria, and inhibition of the MPT (for review,
see Ref. 19). Finally, it has been reported that NO can either
stimulate or inhibit the MPT in liver mitochondria, often
depending upon experimental conditions and the source of
mitochondria (23, 24).
With little evidence assessing the importance of NO as a primary
mediator of bile acid-induced hepatocyte apoptosis, the current study
was performed to elucidate if NO promoted or protected against this
injury. In these studies, freshly isolated rat hepatocytes were used
rather than cultured or hepatoma cell lines so that homeostasis of
physiologic bile acid uptake (25) and endogenous antioxidant pathways
(26) were maintained to better reflect the in vivo
conditions observed during cholestatic liver diseases and so that
physiologic apoptotic pathways were intact. The bile acid chosen for
this study was the sodium salt of glycochenodeoxycholate (GCDC), a
toxic, hydrophobic bile acid that accumulates in the human liver during
cholestasis (27). The objectives of this study were to determine 1) if
NO or its reaction product with superoxide, ONOO
, was
generated from isolated rat hepatocytes or liver mitochondria exposed
to concentrations of GCDC previously observed to promote hepatotoxicity
and the MPT, 2) if modulation of NO status by employing either NOS
inhibitors or NO donors prevented or promoted hepatocyte apoptosis
induced by GCDC, and 3) the effect of NOS inhibitors and NO donors on
mitochondrial pathways involved in GCDC-induced apoptosis.
 |
EXPERIMENTAL PROCEDURES |
Materials--
All chemicals were obtained in reagent grade
quality from suppliers. Bovine serum albumin-fraction V (BSA),
S-nitroso-N-acetylpenicillamine (SNAP), spermine
NONOate (SNN), and the caspase 8 substrate, Ac-IETD-pNA, were obtained
from Calbiochem. DAF-2/DA, 2,7-dichlorodihydrofluorescein diacetate (DCDHF-DA),
NG-monomethyl-N-arginine monoacetate
(L-NMMA), 1400W, and cyclosporin A (CsA) were purchased
from Alexis Biochemicals (San Diego, CA). Z-IETD-FMK (caspase 8 inhibitor) and Z-LEHD-FMK (caspase 9 inhibitor) were purchased from
Enzyme Systems Products (Livermore, CA). Glycochenodeoxycholic acid
(Na+ salt), Griess reagent, and 2,7-dichlorofluorescin
diacetate were obtained from Sigma and Eastman Kodak Co., respectively.
Idebenone was a gift from Takeda Industries (Osaka, Japan), and the
fluorescent probe JC-1 was purchased from Molecular Probes (Eugene, OR).
Isolation of Rat Hepatocytes and Rat Liver
Mitochondria--
Hepatocytes were isolated by a recirculating
collagenase technique from 175-225-g male Sprague-Dawley rats (Sasco,
Inc., Omaha, NE) maintained on a 12-h light-dark cycle and fed standard
laboratory rat chow, as previously described (2). Initial hepatocyte
viability measured by trypan blue exclusion was always >94%. Fresh
hepatocytes were resuspended in a Krebs-Ringers HEPES buffer containing
0.2% BSA (KRH/BSA) to a concentration
1 × 106/ml.
Rat liver mitochondria were isolated by differential centrifugation through a Percoll gradient as described in detail (15).
Determination of NO and ONOO
in Isolated
Hepatocytes and Liver Mitochondria--
Hepatocyte generation of NO or
ONOO
was determined by using specific fluorescent probes
prepared as stock solutions in dimethylformamide, as recently described
by Kojima et al. (28, 29). Cells were preloaded at 37 °C
for 30 min with either 10 µM DAF-2/DA for NO detection or
8 µM DCDHF-DA for detection of ONOO
. Upon
entering the hepatocyte, intracellular esterases hydrolyze the
diacetate moiety, trapping free DAF-2 or DCDHF within the cell (or
mitochondria) that are covalently modified by NO or ONOO
,
respectively. After loading, cells were washed twice and resuspended in
KRH/BSA and preincubated for 30 min either with the antioxidant idebenone, the MPT inhibitor CsA, caspase inhibitors, NOS inhibitors, or appropriate solvent vehicle. Neither solvents nor added compounds alone affected any measurements. Cells were then exposed to 0-500 µM GCDC for 4 h with hourly aliquots removed for
fluorescence determination at 495 nm excitation and 515 nm emission for
DAF-2 or 502 nm excitation and 523 nm emission for DCDHF. Generation of
NO and ONOO
from isolated rat hepatocytes were expressed
as relative fluorescence units/106 cells. Additionally, in
selected experiments hepatocyte NO production was also confirmed by
measuring media nitrite levels using the Griess reagent prepared
according to the manufacturer's instructions as follows. Hepatocytes
(1.2 × 106 cells) were pelleted, and aliquots of
supernatant were incubated with Griess reagent for 10 min at room
temperature before nitrite quantitation at 540 nm. Results were
expressed as µM nitrite based upon a standard curve of
sodium nitrite prepared weekly in KRH/BSA.
Mitochondrial generation of NO and ONOO
was also
determined using DAF-2/DA and DCDHF-DA as described above with the
following modifications. Washed and Percoll gradient-purified
mitochondria were resuspended in a buffer containing 5 mM
HEPES, 50 mM KCl, 2 mM
KH2PO4, 125 mM sucrose, pH 7.4, treated with 1% Chelex 100, and loaded with either 10 µM
DAF-2/DA or 3 µM DCDHF-DA at 28 °C for 30 min. After 2 washes in 5 mM MOPS, 100 mM KCl, 1 mM EGTA, pH 7.4, treated with 1% Chelex 100, mitochondria
was centrifuged at 10,000 × g for 10 min. The final
mitochondrial pellet was resuspended in the same buffer and
preincubated with or without NOS inhibitors for 10 min before the
addition of GCDC. After the addition of GCDC, aliquots of mitochondrial
suspensions were removed for fluorescence determination of NO or
ONOO
as described above.
To confirm the specificity of DAF-2 and DCDHF toward NO and
ONOO
, respectively, studies were carried out with
mitochondria loaded with dichlorofluorescein diacetate, a probe
utilized to detect intracellular hydroperoxide generation (30).
Previous studies from our laboratory showed that mitochondria exposed
to GCDC generate hydroperoxides (31). If DAF-2 and DCDHF specifically
bound NO/ONOO
and not hydroperoxides, we would expect no
effect of NOS inhibitors upon hydroperoxide (dichlorofluorescein
fluorescence) generation. For these studies, dichlorofluorescein
fluorescence was determined at 490-nm excitation and 520-nm emission
and under identical conditions as DAF-2 and DCDHF, as previously
described in detail (2). Results were compared with a standard curve
using 2',7'-dichlorofluorescein as the standard and were expressed as
pmol of dichlorofluorescein/mg of mitochondrial protein.
Determination of Hepatocytes Apoptosis--
Hepatocyte apoptosis
was quantitated by determining the percentage of hepatocytes with
nuclear morphologic changes of apoptosis detected by fluorescence
microscopy of 4,6-diamidino-2-phenylindole-stained fixed hepatocytes,
as previously described (5).
Enzymatic Activity of Caspase 3--
Caspase 3 activity in
hepatocytes was analyzed as follows. Hepatocytes (4-5 × 106 cells) were pelleted, washed with cold KRH buffer, and
resuspended in 1.2 ml of 100 mM HEPES, pH 7.4, containing a
protease inhibitory mixture (P-8340 from Sigma). Cells were lysed by
three freeze-thaw cycles, and a post-mitochondrial supernatant
was obtained by centrifugation at 12,000 × g for 30 min at 4 °C. Caspase activity was measured by incubating
supernatants (
300-600 µg of protein) with the chromogenic substrate Ac-DEVD-pNA (150 µM) at 37 °C for
1 h, and the cleavage product was determined at 405 nm. Results
were expressed as absorbance/mg protein/h.
Measurement of the Mitochondrial Permeability
Transition--
The MPT was measured spectrophotometrically as
described in detail (15). Briefly, hepatic mitochondria (1.5-3.0 ml)
were incubated at 25 °C for 5 min alone or in the presence of a NOS inhibitor or SNAP. After the preincubation period, 100 µM
CaCl2, 5 mM sodium succinate, and 5 µM rotenone (in dimethylformamide) were added to
mitochondria, and the absorbance at 540 nm was monitored for 5 min. The
MPT was then induced by the addition of 100-200 µM GCDC,
and absorbance was monitored for an additional 5 min. After the MPT
experiment, some mitochondrial samples were centrifuged immediately at
10,000 × g for 30 min at 4 °C to isolate the
mitochondrial pellet for immunoblot analysis of cytochrome c
as described below.
Flow Cytometry--
Flow cytometric analysis was performed to
determine the effect of NO donors on GCDC-induced MPT in freshly
isolated hepatocytes as previously described in detail (14). Briefly,
hepatocytes were treated with 0 or 100 µM GCDC in the
absence or presence of 0.5 mM SNAP or SNN for 3 h.
Hourly aliquots of cells were removed, loaded with 7.6 µM
JC-1 or 3 µM propidium iodide for 15 min at 22 °C in
the dark, and washed with KRH buffer at 4 °C before flow cytometry
on a BD PharMingen FACSCalibur using CELLQuest software. In actively
respiring mitochondria, JC-1 aggregates form, and the intensity of
their fluorescence at 590 nm is proportional to the mitochondria 
and indicative of a closed MPT pore. Approximately 10,000 cells were
analyzed for each time point and treatment. The content of JC-1
aggregates was determined only in live cells, as indicated by their
lack of uptake of propidium iodide.
Immunoblot Analysis of Cytochrome c Release from Liver
Mitochondria--
Immunoblot analysis of cytochrome c was
performed by separating mitochondrial proteins on a 12.5% SDS-PAGE gel
before transferring proteins onto an Immobilon-P membrane (Fisher) in a
buffer consisting of 25 mM Tris-HCl, 192 mM
glycine, 10% methanol (32). After transfer, the blots were incubated
with 1% nonfat dry milk (Bio-Rad) followed by incubation with 1 µg/ml mouse anti-cytochrome c monoclonal antibody (BD
PharMingen). After 3 washes with phosphate-buffered saline containing
0.1% Tween 20, blots were incubated with 1:1000 dilution of
horseradish peroxidase polyclonal anti-mouse Ig (BD PharMingen). After
three washes with phosphate-buffered saline with Tween, cytochrome
c reactivity was developed colorimetrically using the
Opti-4CN substrate kit according to the manufacturer's instruction,
scanned, and quantitated by densitometry using UN-SCAN IT gel software
(Silk Scientific Inc., UT). Cytochrome c content was
expressed as relative densitometry units.
Statistical Analysis--
Mean and S.E. were calculated for each
time point. Comparisons among groups were performed by analysis of
variance and the Schefe test or t test where
appropriate. A p value of < 0.05 was considered
statistically significant.
 |
RESULTS |
GCDC Stimulates NO and ONOO Generation from Isolated Rat
Hepatocytes and Liver Mitochondria--
GCDC caused significant
apoptosis in hepatocytes after 2 h of exposure to 50 and 100 µM GCDC (Fig.
1a), the latter concentration being chosen for subsequent experiments. To determine whether GCDC
stimulated NO or ONOO
generation in rat hepatocytes or
liver mitochondria, the fluorescent probes DAF-2/DA and DCDHF-DA were
utilized for detection of NO and ONOO
, respectively (28,
29). Rat hepatocytes incubated in the absence of GCDC generated very
low levels of NO and ONOO
(Fig. 1, b-c).
Exposure to GCDC (25-500 µM) resulted in concentration- and time-dependent increases of cellular NO and
ONOO
production beginning at 1 h of incubation,
indicating that GCDC stimulation of NO/ONOO
generation
preceded induction of apoptosis. Evidence that the observed increases
of DAF-2 and DCDHF fluorescence represented hepatocyte
NO/ONOO
generation was provided by the significant
reduction of NO and ONOO
(90% and >75%, respectively)
in the presence of the NOS inhibitor L-NMMA (1 mM) (Fig. 1) and 1400W (Fig.
2), a more selective inhibitor of
inducible NOS (33).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 1.
GCDC stimulates apoptosis
(a) and generation of NO (b) and
ONOO (c) from isolated rat
hepatocytes. Hepatocytes (106/ml) were loaded with
either 10 µM DAF-2 or 8 µM DCDHF (for NO
and ONOO determinations, respectively) in KRH/BSA buffer
for 30 min at 37 °C before exposure to GCDC (0-500
µM). Where indicated, the NOS inhibitor
L-NMMA (1 mM) was preincubated for 30 min
before the addition of 500 µM GCDC. Values are expressed
as means ± S.E. of at least five experiments.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 2.
NOS inhibitors prevent the GCDC-induced
generation of NO (a), ONOO (b),
but not hydroperoxides (c) from rat liver mitochondria
exposed to GCDC. Liver mitochondria ( 1.0 mg/ml) were loaded
with either 10 µM DAF-2, 3 µM DCDHF, or 8 µM dichlorofluorescein diacetate (for NO,
ONOO , and hydroperoxide determinations, respectively) for
30 min at 28 °C and exposed to GCDC (100 µM) for 10 min. NOS inhibitors were preincubated for 5 min before the addition of
GCDC. As shown in the figure, NOS inhibitors reduced NO and
ONOO levels from GCDC-treated mitochondria without
affecting hydroperoxide generation, supporting the specificity of DAF
and DCDHF toward NO and ONOO , respectively. Values are
expressed as means ± S.E. of at least five experiments.
|
|
GCDC stimulated NO/ONOO
production from liver
mitochondria within 1 min, increasing NO/ONOO
levels by
4-6-fold by the end of the 10-min incubation (Fig. 2,
a-b). Because NOS activity is also detectable in
mitochondria (34), we examined the effect of L-NMMA and
1400W on mitochondria exposed to GCDC. As seen from Fig. 2,
a-c, inhibition of NOS reduced NO and ONOO
production in mitochondria. Because GCDC also stimulated hydroperoxide generation from liver mitochondria (15, 31), we determined whether NOS
inhibitors affected hydroperoxide generation from mitochondria exposed
to GCDC. GCDC caused significant hydroperoxide formation in
mitochondria, which was resistant to NOS inhibitors (Fig.
2c). These findings support prior observations (28, 29) that
DAF-2 and DCDHF react poorly with reactive oxygen species other than NO
and ONOO
and can be utilized as effective probes to
detect hepatocyte generation of NO and ONOO
. Because of
the close correlation between NO and ONOO
generation and
their suppression by NOS inhibitors, in subsequent experiments only NO
levels (DAF-2 fluorescence) were determined.
Effect of NOS Inhibition on Apoptosis--
The increased
generation of NO in rat hepatocytes and liver mitochondria exposed to
GCDC raised the possibility that NO or its metabolites could function
as an important mediator or cell signal responsible for the cellular
changes observed during GCDC-induced hepatocyte injury (5, 14, 15).
Therefore, we examined whether modulation of NO status prevented or
potentiated GCDC-induced apoptosis compared with other inhibitors of
hepatocyte apoptosis. GCDC (100 µM) caused
substantial hepatocyte apoptosis by 4 h (40.8 ± 5.4%),
which was reduced by >75% by inhibitors of either caspase 8 (Z-IETD-FMK) or 9 (Z-LEHD-FMK), CsA, or idebenone (Fig.
3a). These inhibitors of
apoptosis also completely suppressed GCDC-induced generation of NO
(Fig. 3b). In contrast, GCDC-induced apoptosis was
unaffected by pretreatment with NOS inhibitors despite complete inhibition of cellular NO generation (Fig. 3a). These
findings indicate that endogenously produced NO in GCDC-treated rat
hepatocytes does not mediate nor stimulate apoptosis.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of NOS inhibitors on GCDC-induced
apoptosis (a) and NO generation (b)
from isolated rat hepatocytes. Rat hepatocytes were prepared as
described in Fig. 1 and pretreated for 30 min with NOS inhibitors (1 mM L-NMMA or 100 µM 1400W) before
induction of apoptosis with GCDC (100 µM). For
comparative purposes, additional inhibitors of GCDC-induced apoptosis
were also employed. GCDC-induced apoptosis and NO generation were all
significantly reduced by the antioxidant idebenone (Ideb;100
µM), the MPT blocker CsA (5 µM), and
inhibitors of caspase 8 (25 µM Z-IETD-FMK) and caspase 9 (20 µM Z-LEHD-FMK). However, NOS inhibitors had no effect
upon GCDC-induced apoptosis, despite significantly reducing NO
generation.
|
|
Effect of NO Donors on Apoptosis and Mitochondrial
Perturbations--
Although inhibition of cellular NO generation by
NOS inhibitors failed to alter the course of GCDC-induced
apoptosis, we performed additional studies to determine whether further
elevating NO levels by exogenous administration of NO donors (SNAP and
SNN) influenced this process, as demonstrated in other models of
cellular toxicity (20, 22). Indeed, preincubation with NO donors
significantly reduced GCDC-induced apoptosis by ~65% for SNAP
(0.5-1.0 mM) and 100% in the case of 0.5 mM
SNN (Figs. 4a and
5). To compare NO production with
hepatocyte apoptosis, we measured extracellular nitrite production, a
primary metabolite of NO (Fig. 4b). Compared with untreated
cells, GCDC stimulated a 3-fold increase in nitrite levels by 4 h
of incubation, approximately the increase in DAF-2 fluorescence
observed between untreated and 100 µM GCDC-treated hepatocytes (Fig. 1a). Moreover, cells pretreated with NO
donors had substantially elevated nitrite levels, 20-30-fold by SNAP (0.5-1.0 mM) and 400-fold by SNN (0.5 mM)
(Fig. 4b, inset). These data suggesting that high
levels of NO were necessary for inhibition of apoptosis. One postulated
mechanism responsible for NO-dependent inhibition of
apoptosis is the nitrosylation and inactivation of caspases (19, 20).
Therefore, we determined caspase 3 activity in cells exposed to GCDC
with and without NO donors. Caspase 3 is a downstream, effector caspase
involved in the execution of apoptotic cell death (35). Increased
hepatocyte caspase 3 activity measured after 3 h of incubation
with 100 µM GCDC was inhibited by SNAP (Fig.
4c).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of NO donors on GCDC-induced apoptosis
(a), media nitrite levels (b), and
caspase 3 activity (c). Hepatocytes were
preincubated for 30 min with either SNAP (0.5-1.0 mM)
or SNN (0.5 mM) before induction of apoptosis
with GCDC (100 µM). Cells were removed hourly for
quantitation of apoptosis (4,6-diamidino-2-phenylindole staining)
and nitrite levels and after 3 h for measurement of caspase
3 activity. a, SNAP and SNN significantly reduced
GCDC-induced apoptosis by ~64 and 100%, respectively, by 4 h.
b, SNAP and SNN increased nitrite levels from hepatocytes by
20-30-fold for SNAP and ~400-fold for SNN, by 4 h when compared
with untreated hepatocytes. GCDC (100 µM) also
significantly increased nitrite levels by 4 h compared with
untreated cells. c, GCDC (100 µM) stimulated
caspase 3 activity after 3 h incubation, which was prevented by
pretreatment with either SNAP or SNN. abs, absorbance.
|
|

View larger version (115K):
[in this window]
[in a new window]
|
Fig. 5.
Nuclear morphology of
4,6-diamidino-2-phenylindole-stained rat hepatocytes exposed to
100 µM GCDC (or vehicle) for 3 h and pretreated with either an NO donor SNN (0. 5 mM) or NOS inhibitor 1400W (100 µM). Also shown are hepatocytes
pretreated with CsA (5 µM) or idebenone (100 µM). The arrowheads identify fragmented nuclei
of apoptotic cells. The figure indicates that GCDC is a potent inducer
of hepatocyte apoptosis, which is prevented by elevated NO, CsA, and
idebenone but was not affected by NOS inhibition. The bar in
the bottom right panel is 10 mm.
|
|
Finally, we determined if NO modulation had any direct effect on
mitochondrial pathways involved in bile acid-induced apoptosis. We
specifically examined the effect of NOS inhibitors and SNAP on the MPT
and cytochrome c release in liver mitochondrial suspensions exposed to GCDC and on GCDC-induced depolarization of isolated rat
hepatocytes by flow cytometry. Both inhibition of NO production (by
L-NMMA and 1400W) and enhancement of mitochondrial NO
levels by (SNAP) had no effect on the induction of MPT or cytochrome c release by GCDC (100-200 µM) in isolated
mitochondria (Fig. 6). Similarly, flow
cytometry demonstrated that fluorescence of JC-1 aggregates, indicative
of an intact mitochondrial 
and a closed MPT pore, decreased
significantly by 2 h in hepatocytes treated with GCDC (100 µM) compared with untreated cells and that mitochondrial
depolarization occurred early in the induction of bile acid-induced
hepatocyte apoptosis (Fig. 7). However,
preincubation of cells with either 0.5 mM SNAP or SNN
failed to prevent this bile acid-induced mitochondrial depolarization.
Thus, the inhibition of apoptosis by NO was associated with reduced
caspase 3 activity but without any direct effect on mitochondrial
pathways involved in GCDC-induced apoptosis.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 6.
NO modulation fails to prevent the
GCDC-induced MPT (a) or release of cytochrome
c (b) from rat liver
mitochondria. Modulation of mitochondrial NO by NOS inhibitors
(100 µM L-NMMA or 10 µM 1400W)
or the NO donor SNAP (500 µM) was performed by
preincubating mitochondria for 10 min before induction of the MPT by
GCDC (100-200 µM). GCDC caused rapid, high amplitude
swelling of mitochondria, which was quantitated by the change in
absorbance at 540 nm over a 5-min incubation. After the 5-min exposure
to GCDC, mitochondria were isolated by centrifugation, analyzed for
mitochondrial cytochrome c content by immunoblotting, and
expressed as relative densitometric units compared with untreated
(control) mitochondria. GCDC promoted mitochondrial cytochrome
c loss compared with untreated mitochondria, which was
unaffected by modulators of NO. Values are means ± S.E. of three
experiments. The inset shows a typical immunoblot of
mitochondrial cytochrome c remaining after the specific
treatments.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 7.
The Effect of NO on GCDC-induced collapse of
mitochondrial  in freshly
isolated hepatocytes. Isolated rat hepatocytes were exposed to 100 µM GCDC in the absence or presence of 0.5 mM
SNAP or SNN. Hourly aliquots were removed, loaded with 7.6 µM JC-1 for 15 min at 22 °C, and washed with KRH
buffer before fluorescence determination at 590 nm. JC-1 aggregates,
which represent an intact mitochondrial  , were significantly
reduced by 2 h of treatment with GCDC compared with untreated
cells. Preincubation of NO donors with hepatocytes failed to prevent
this bile acid-induced mitochondrial depolarization from isolated rat
hepatocytes. NO donors alone failed to affect JC-1 aggregate production
when compared with control cells (not shown). The numbers above the
bars indicate the % of the population of live cells, which
contain the amount of fluorescence under the
bar.
|
|
 |
DISCUSSION |
In the present study, we have demonstrated that neither NO nor
ONOO
play a role in mediating hepatocellular apoptosis
induced by hydrophobic bile acids and that elevated NO levels may have
an anti-apoptotic effect that does not involve mitochondrial pathways of apoptosis. By using fluorescent probes specific for NO and ONOO
, we have provided evidence that GCDC stimulates
NO/ONOO
production from both freshly isolated rat
hepatocytes and liver mitochondria by a NOS-dependent
pathway. These probes offer many benefits for assessing
NO/ONOO
status including the ability to detect low
intracellular concentrations (which may allow detection of NO from
constitutively produced NO) and their lack of reactivity toward other
reactive species such as superoxide and hydroperoxides (28, 29, 36).
Corroboration of the lack of reactivity of these probes toward
hydroperoxides was demonstrated in our experimental model.
These results are the first to demonstrate stimulation of NO and
ONOO
generation in both isolated rat hepatocytes and
liver mitochondria by a hydrophobic bile acid under conditions that may
exist in the cholestatic liver. Similar results were recently reported in endothelial vascular cells exposed to bile acids, in which the
hydrophobicity of the bile acids correlated with their capacities to
increase NO production (37). In addition to NO production, ONOO
generation in rat hepatocytes and liver mitochondria
further demonstrates the GCDC stimulation of superoxide. We have
previously shown that ROS are generated by the respiratory chain of
mitochondria exposed to bile acids (38) and have proposed that impaired
electron transport (39) was responsible for mitochondrial superoxide generation. The mechanisms responsible for the increased generation of
NO from rat hepatocytes or liver mitochondria exposed to GCDC are
unclear. Under normal physiological conditions, basal low levels of NO
within the liver are controlled by endothelial NOS, which in turn is
primarily regulated by intracellular calcium flux and calmodulin
binding (40). However, upon stimulation by cytokines or microbial
products such as lipopolysaccharides, induction of a distinct NOS,
inducible NOS (iNOS), results in rapid synthesis of NO. Regulation of
this NOS isoform occurs at both transcriptional and post-translational
steps by a variety of signal-transducing agents including
phosphatidylinositol 3-kinase (reviewed in Ref. 41). Inasmuch as
phosphatidylinositol 3-kinase activation has been shown to prevent
hepatocyte apoptosis induced by hydrophobic bile acids (but not GCDC)
(42, 43), it is unclear whether the NO stimulated by GCDC is the result
of phosphatidylinositol 3-kinase regulation of either iNOS or
"constitutive" NOS isoforms. Further characterization of
iNOS-dependent NO production from rat hepatocytes was
recently reported by Fariss and co-workers (44, 45). Their studies
revealed time-dependent increases of nitrite formation and
expression of iNOS and NOS enzymatic activity after 3 h of
incubation. Because we were unable to demonstrate increased iNOS
expression by GCDC (data not shown), it is unlikely that iNOS induction
was responsible for the observed GCDC-stimulated NO that appeared
within 1 h of incubation.
Production of NO in both isolated rat hepatocytes and liver
mitochondria exposed to GCDC suggested a possible important regulatory role of NO during bile acid-induced hepatotoxicity. Although others have shown that bile acids may promote hepatocyte apoptosis through pathways involving activation of caspase 8 (46), protein kinase c (47),
and Fas aggregation (43), our laboratory has reported ROS generation
and MPT as key steps in bile acid-induced apoptosis. As a
cell-signaling agent and biologically relevant free radical, NO has
been found to either promote or prevent apoptosis. For example,
stimulation of NO generation by induction of iNOS may promote apoptosis
in macrophages and hepatocytes (48, 49) and cause release of cytochrome
c from mitochondria (50, 51). Despite conflicting data,
however, the preponderance of evidence strongly supports the notion
that NO, supplied exogenously or stimulated via iNOS, acts as an
anti-apoptotic or cell survival factor, particularly during tumor
necrosis factor-
or Fas ligand-dependent hepatocyte
apoptosis (19-22). Proposed mechanisms for the anti-apoptotic effects
of NO include 1) increased cGMP production, 2) induction of
cytoprotective genes such as heat shock proteins, and 3) inhibition of
caspase activities (for review, see Ref. 19). Of particular relevance
to the current study, Billiar and co-workers (19, 20) provided evidence
that NO can inhibit caspases through direct nitrosylation of key
sulfhydryl moieties found in all caspases, thus controlling activation
of these proteases by redox modification. In the current study, by
utilizing two distinct NOS inhibitors, L-NMMA, a
nonspecific inhibitor, and 1400W, a specific inhibitor of iNOS activity
(52), we observed that suppression of GCDC-stimulated endogenous NO
production (as measured by both intracellular DAF fluorescence and
extracellular nitrite accumulation), failed to alter induction of
hepatocyte apoptosis. One likely explanation for the lack of effect of
NOS inhibitors is that the amount of NO produced was insufficient to
modulate pathways critical to the execution of apoptosis. However, in
concordance with hepatocyte apoptosis induced by tumor necrosis
factor-
or Fas ligand (19-22), substantially elevating NO
concentrations with two NO donors afforded significant protection
against GCDC-induced apoptosis by a mechanism likely involving
inhibition of caspase 3. Furthermore, these data show that SNN, a
rapidly yielding NO donor, produced greater quantities of NO and
inhibition of apoptosis and caspase 3 activity compared with SNAP, a
slower, less "efficient" NO donor (53), consistent with a
relationship between NO concentration and protection against apoptosis.
An additional mechanism for the protection of NO against bile
acid-induced apoptosis could be by preventing mitochondrial perturbations. In this regard, NO has been shown to both induce (50,
54) and inhibit MPT and/or cytochrome c release (22, 24) in
a variety of experimental conditions and cell types. Results from the
present study clearly demonstrate that modulating NO levels with either
NOS inhibitors or NO donors had no effect on two key mitochondrial
factors involved in GCDC-induced apoptosis (14), the MPT and cytochrome
c release. Thus the protective effects of NO in our model do
not appear to involve mitochondria directly, but rather, interactions
with essential cytosolic caspases.
In our experiments, NO generation was also completely suppressed by a
variety of inhibitors of hepatocyte apoptosis that do not directly
affect NOS activity. The choice of these inhibitors allowed examination
of the potential mechanisms and locations of NO production relative to
mechanisms of bile acid-induced hepatocyte apoptosis. For instance,
inhibition of NO and apoptosis by CsA raises the intriguing possibility
that the NO generated from GCDC-treated hepatocytes is contingent upon
induction of the MPT. Interestingly, one report describes mitochondrial
NOS-dependent stimulation of cytochrome c
release, which was not mediated by the MPT but rather through formation
of ONOO
(50). Clearly, the prevention of NO generation by
multiple inhibitors of GCDC-induced apoptosis at both upstream (caspase 8 inhibition) and downstream (caspase 9 inhibition) locations suggests
that NO generation occurs as a consequence of cellular apoptotic events
in this model.
Another potential site of regulation of hepatocyte apoptosis by NO are
protein kinases and mitogen-activated protein kinases. Hydrophobic bile
acids have been shown to promote hepatocyte apoptosis by
ligand-independent activation of Fas and TRAIL death receptor cascades
(55, 56) and subsequent activation of a variety of signal transduction
pathways including caspases (46) and protein kinases (47). Among those
members of the protein kinase family involved in cell apoptosis,
mitogen-activated protein kinases have been reported to protect
hepatocytes against bile acid-induced apoptosis (57, 58), potentially
explaining the therapeutic effects of the hydrophilic bile acid,
tauroursodeoxycholic acid, in cholestatic liver diseases (59). Qiao
et al. (58) recently showed in primary hepatocytes that
deoxycholic acid caused ligand-independent activation of epidermal
growth factor receptor, which led to mitogen-activated protein kinase
activation via phosphatidylinositol 3-kinase. Activation of this
pathway afforded cytoprotection through enhanced expression c-FLIP
isoforms that inhibit procaspase 8 cleavage. Conversely, inasmuch as
ROS generation has been shown to activate c-Jun
NH2-terminal kinase and other protein kinases (60), it is
proposed that bile acid-stimulated ROS generation may be an upstream
event in hepatocytes exposed to hydrophobic bile acids that may trigger
activation of protein kinases involved in promoting cellular apoptosis.
Finally, a recently characterized member of the mitogen-activated
protein kinase family, apoptosis signal-regulating kinase (ASK-1) can be activated by cytotoxic stimuli including Fas, tumor necrosis factor-
, or ROS and is essential for the induction of apoptosis in a
number of differentiated cell lines (61, 62). Overexpression of ASK-1
leads to activation of JNK and other mitogen-activated protein kinases
causing induction of apoptosis in certain cell types (63), although
there is no evidence for the role of ASK-1 activation during hepatocyte
apoptosis. Because NO has been shown to regulate protein kinase
expression (64), determining the role of NO interactions with these
various protein kinase families in bile acid-induced apoptosis will
require further investigation.
In summary, our findings support a potential protective role of high
levels of NO during bile acid-induced hepatocyte apoptosis. Although GCDC did stimulate NO generation in hepatocytes and
mitochondria, the low levels of NO did not play a role in mediating or
protecting against hepatocyte apoptosis. However, exogenous addition of
NO supplied by NO donors or up-regulation of cellular iNOS by chemical or gene transfer techniques or by stimulation of NF
B might provide an effective cell survival strategy for reducing bile acid-induced cellular injury. Other factors that regulate NO synthesis and NOS
expression during bile acid toxicity and cholestasis require further
investigation. If accumulation of hydrophobic bile acids is indeed a
primary factor in the pathogenesis of cholestatic liver diseases, then
results from this study may provide a potential therapeutic strategy in
addition to reducing oxidant stress and inhibiting the MPT (14, 15) for
preventing or reducing the hepatocellular damage observed clinically in
cholestatic liver injury.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grant RO1 DK-38446, the Abby Bennett Liver Research Fund, and
postdoctoral fellowship grants from the American Liver Foundation and
the Cystic Fibrosis Foundation (to B. Y.). This work was presented in
part at the 52nd annual meeting of the American Association for the
Study of Liver Diseases, November 9-13, 2001, Dallas, TX
(Gumpricht, E., Deveraux, M. W., Dahl, R., and Sokol, R. J. (2001) Hepatology 34, 272A (Abstr. 399)).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Box B290, The
Children's Hospital, 1056 E. 19th Ave., Denver, CO 80218. Tel.: 303-861-6669; Fax: 303-764-8025; E-mail:
sokol.ronald@tchden.org.
Published, JBC Papers in Press, May 2, 2002, DOI 10.1074/jbc.M112305200
 |
ABBREVIATIONS |
The abbreviations used are:
ROS, reactive oxygen
species;
MPT, mitochondrial permeability transition;
NOS, nitric-oxide
synthase;
iNOS, inducible NOS;
GCDC, glycochenodeoxycholate;
BSA, bovine serum albumin;
SNAP, S-nitroso-N-acetylpenicillamine;
DAF-2/DA, 4,5-diaminofluorescein;
NONOate, [N-(2-aminoethyl)-N-(2-hydroxy-2-nitrohydrazino)-1,2-ethylenediamine;
SNN, spermine NONOate;
DCDHF-DA, dichlorodihydrofluorescein
diacetate;
L-NMMA, NG-monomethyl-N-arginine monoacetate;
CsA, cyclosporin A;
KRH, Krebs-Ringers HEPES;
MOPS, 4-morpholinepropanesulfonic acid;
ASK-1, apoptosis
signal-regulating kinase.
 |
REFERENCES |
| 1.
|
Bove, K. E.,
Daugherty, C. C.,
Tyson, W.,
Mierau, G.,
Heubi, J. E.,
Balistreri, W. F.,
and Setchell, K. D.
(2000)
Pediatr. Dev. Pathol.
3,
1-16[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Sokol, R. J.,
Winklhofer-Roob, B. M.,
Devereaux, M. W.,
and McKim, J. M.
(1995)
Gastroenterology
109,
1249-1256[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Galle, P. R.,
Theilmann, L.,
Raedsch, R.,
Otto, G.,
and Stiehl, A.
(1990)
Hepatology
12,
486-491[Medline]
[Order article via Infotrieve]
|
| 4.
|
Patel, T.,
Bronk, S. F.,
and Gores, G. J.
(1994)
J. Clin. Invest.
94,
2183-2192[Medline]
[Order article via Infotrieve]
|
| 5.
|
Gumpricht, E.,
Devereaux, M. W.,
Dahl, R. H.,
and Sokol, R. J.
(2000)
Toxicol. Appl. Pharmacol.
164,
102-111[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Rodrigues, C. M.,
Fan, G.,
Wong, P. Y.,
Kren, B. T.,
and Steer, C. J.
(1998)
Mol. Med.
4,
165-178[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Rodrigues, C. M.,
Fan, G., Ma, X.,
Kren, B. T.,
and Steer, C. J.
(1998)
J. Clin. Invest.
101,
2790-2799[Medline]
[Order article via Infotrieve]
|
| 8.
|
Crompton, M.
(1999)
Biochem. J.
341,
233-249[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Pastorino, J. G.,
Snyder, J. W.,
Serroni, A.,
Hoek, J. B.,
and Farber, J. L.
(1993)
J. Biol. Chem.
268,
13791-13798[Abstract/Free Full Text]
|
| 10.
|
Kroemer, G,
and Reed, J. C.
(2000)
Nat. Med.
6,
513-519[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Botla, R.,
Spivey, J. R.,
Aguilar, H.,
Bronk, S. F.,
and Gores, G. J.
(1995)
J. Pharmacol. Exp. Ther.
272,
930-938[Abstract/Free Full Text]
|
| 12.
|
Gores, G. J.,
Miyoshi, H.,
Botla, R.,
Aguilar, H. I.,
and Bronk, S. F.
(1998)
Biochim. Biophys. Acta
1366,
167-175[Medline]
[Order article via Infotrieve]
|
| 13.
|
Rolo, A. P.,
Oliveira, P. J.,
Moreno, A. J. M.,
and Palmeira, C. M.
(2000)
Toxicol. Sci.
57,
177-185[Abstract/Free Full Text]
|
| 14.
|
Yerushalmi, B.,
Dahl, R.,
Devereaux, M. W.,
Gumpricht, E.,
and Sokol, R. J.
(2001)
Hepatology
33,
616-626[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Sokol, R. J.,
Straka, M. S.,
Dahl, R.,
Devereaux, M. W.,
Yerushalmi, B.,
Gumpricht, E.,
Elkins, N.,
and Everson, G.
(2001)
Pediatr. Res.
49,
519-531[Medline]
[Order article via Infotrieve]
|
| 16.
|
Kowaltowski, A. J.,
Castilho, R. F.,
and Vercesi, A. E.
(2001)
FEBS Lett.
495,
12-15[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Griffith, O. W.,
and Stuehr, D. J.
(1995)
Annu. Rev. Physiol.
57,
707-736[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Kroncke, K-D.,
Suschek, C. V.,
and Kolb-Bachofen, V.
(2000)
Antioxid. Redox Signal.
2,
585-605[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Chung, H-T.,
Pae, H-O.,
Choi, B-M.,
Billiar, T. R.,
and Kim, Y-M.
(2001)
Biochem. Biophys. Res. Commun.
282,
1075-1079[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Kim, Y-M.,
Talanian, R. V.,
and Billiar, T. R.
(1997)
J. Biol. Chem.
272,
31138-31148[Abstract/Free Full Text]
|
| 21.
|
Kim, Y-M.,
Kim, T-H.,
Chung, H-T.,
Talanian, R. V.,
Yin, X-M.,
and Billiar, T. R.
(2000)
Hepatology
32,
770-778[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Hatano, E.,
Bennett, B. L.,
Manning, A. M.,
Qian, T.,
Lemasters, J. J.,
and Brenner, D. A.
(2001)
Gastroenterology
120,
1251-1262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Balakirev, M. Y.,
Khramtsov, V. V.,
and Zimmer, G.
(1997)
Eur. J. Biochem.
246,
710-718[Medline]
[Order article via Infotrieve]
|
| 24.
|
Brookes, P. S.,
Salinas, E. P.,
Darley-Usmar, K.,
Eiserich, J. P.,
Freeman, B. A.,
Darley-Usmar, V. M.,
and Anderson, P. G.
(2000)
J. Biol. Chem.
275,
20474-20479[Abstract/Free Full Text]
|
| 25.
|
Suchy, F. J.
(1993)
Semin. Liver Dis.
13,
235-247[Medline]
[Order article via Infotrieve]
|
| 26.
|
Glascott, P. A.,
Gilfor, E.,
and Farber, J. L.
(1992)
Mol. Pharmacol.
41,
1155-1162[Abstract]
|
| 27.
|
Greim, H.,
Czygan, P.,
Schaffner, F.,
and Popper, H.
(1972)
Biochem. Med.
8,
280-286
|
| 28.
|
Kojima, H.,
Sakurai, K.,
Kikchi, K.,
Kawahara, S.,
Kirino, Y.,
Nagoshi, H.,
Hirata, Y.,
Akaike, T.,
Maeda, H.,
and Nagano, T.
(1997)
Biol. Pharm. Bull.
20,
1229-1232[Medline]
[Order article via Infotrieve]
|
| 29.
|
Kojima, H.,
Nakatsubo, N.,
Kikchi, K.,
Kawahara, S.,
Kirino, Y.,
Nagoshi, H.,
Hirata, Y,
and Nagano, T.
(1998)
Anal. Chem.
70,
2446-2453[Medline]
[Order article via Infotrieve]
|
| 30.
|
Cathcart, R.,
Schwiers, E.,
and Ames, B. N.
(1983)
Anal. Biochem.
134,
111-116[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Shivaram, K. N.,
Winklhofer-Roob, B. W.,
Straka, M. S.,
Devereaux, M. S.,
Everson, G.,
Mierau, G. W.,
and Sokol, R. J.
(1998)
Free Radic. Biol. Med.
25,
480-492[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Towbin, H.,
Staehelin, T.,
and Gordon, J.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
4350-4354[Abstract/Free Full Text]
|
| 33.
|
Boer, R.,
Ulrich, W. R.,
Klein, T.,
Mirau, B.,
Haas, S.,
and Baur, I.
(2000)
Mol. Pharmacol.
58,
1026-1034[Abstract/Free Full Text]
|
| 34.
|
Tatoyan, A.,
and Giulivi, C.
(1998)
J. Biol. Chem.
273,
11044-11048[Abstract/Free Full Text]
|
| 35.
|
Scaffidi, C.,
Fulda, S.,
Srinivasan, A.,
Friesen, C., Li, F.,
Tomaselli, K. J.,
Debatin, K. M.,
Krammer, P. H.,
and Peter, M. E.
(1998)
EMBO J.
17,
1675-1687[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Crow, J. P.
(1997)
Nitric Oxide
1,
145-157[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Nakajima, T.,
Okuda, Y.,
Chisaki, K.,
Shin, W-S.,
Iwasawa, K.,
Morita, T.,
Matsumoto, A.,
Suzuki, J. I.,
Suzuki, S.,
Yamada, N.,
Toyo-Oka, T.,
Nagai, R.,
and Omata, M.
(2000)
Br. J. Pharmacol.
130,
1457-1467[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Winklhofer-Roob, B. W.,
McKim, J. M.,
Devereaux, M. S.,
and Sokol, R. J.
(1996)
Hepatology
24,
338[CrossRef] (Abstr. 845)
|
| 39.
|
Krahenbuhl, S.,
Talos, C.,
Fischer, S.,
and Reichen, J.
(1994)
Hepatology
19,
471-479[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Michel, J. B.,
Feron, O.,
Sacks, D.,
and Michel, T. J.
(1997)
J. Biol. Chem.
272,
15583-15586[Abstract/Free Full Text]
|
| 41.
|
Wright, K. L.,
and Ward, S. G.
(2000)
Mol. Cell Biol. Res. Commun.
4,
137-143[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Rust, C.,
Karnitz, L. M.,
Paya, C. V.,
Moscat, J.,
Simari, R. D.,
and Gores, G. J.
(2000)
J. Biol. Chem.
275,
20210-20216[Abstract/Free Full Text]
|
| 43.
|
Takikawa, Y.,
Miyoshi, H.,
Rust, C.,
Roberts, P.,
Siegel, R.,
Mandal, P. K.,
Millikan, R. E.,
and Gores, G. J.
(2001)
Gastroenterology
120,
1810-1817[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Nicholls-Grzemski, F. A.,
Tirmenstein, M. A.,
and Fariss, M. W.
(1999)
Biochem. Pharmacol.
57,
1223-1226[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Tirmenstein, M. A.,
Nicholls-Grzemski, F. A.,
Schmittgen, T. D.,
Zakrajsek, B. A.,
and Fariss, M. W.
(2000)
Toxicol. Sci.
53,
56-62[Abstract/Free Full Text]
|
| 46.
|
Faubion, W. A.,
Guicciardi, M. E.,
Miyoshi, H.,
Bronk, S. F.,
Roberts, P. J.,
Svingen, P. A.,
Kaufmann, S. H.,
and Gores, G. J.
(1999)
J. Clin. Invest.
103,
137-145[Medline]
[Order article via Infotrieve]
|
| 47.
|
Gonzalez, B.,
Fisher, C.,
and Rossner, B. G.
(2000)
Mol. Cell. Biochem.
207,
19-27[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Brune, B.,
Sandau, K.,
and von Knethen, A.
(1998)
Biochemistry (Mosc)
63,
817-825[Medline]
[Order article via Infotrieve]
|
| 49.
|
Wang, J. H.,
Redmond, H. P., Wu, Q. D.,
and Bouchier-Hayes, D.
(1998)
Am. J. Physiol.
275,
G1117-G1126[Medline]
[Order article via Infotrieve]
|
| 50.
|
Ghafouritar, P.,
Schenk, H.,
Klein, S. D.,
and Richter, C.
(1999)
J. Biol. Chem.
274,
31185-31188[Abstract/Free Full Text]
|
| 51.
|
Borutaite, V.,
Morkuniere, R.,
and Brown, G. C.
(1999)
Biochim. Biophys. Acta
1453,
41-48[Medline]
[Order article via Infotrieve]
|
| 52.
|
Koarai, A.,
Ichinose, M.,
Sugiura, H.,
Yamagata, S.,
Hattori, T.,
and Shirato, K.
(2000)
Pulm. Pharmacol. Ther.
13,
267-275[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Hou, Y.-C,
Janczuk, A.,
and Wang, P. G.
(1999)
Curr. Pharm. Des.
5,
417-441[Medline]
[Order article via Infotrieve]
|
| 54.
|
Hortelano, S.,
Dallaporta, B.,
Zamzami, N.,
Hisch, T.,
Susin, S. A.,
Marza, I.,
Bosca, L.,
and Kroemer, G.
(1997)
FEBS Lett.
410,
373-377[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Higuchi, H,
Bronk, S. F.,
Takikawa, Y.,
Werneburg, N.,
Takimoto, R., El-,
Deiry, W.,
and Gores, G. J.
(2001)
J. Biol. Chem.
276,
38610-38618[Abstract/Free Full Text]
|
| 56.
|
Soderman, T.,
Bronk, S. F.,
Roberts, P. H.,
Miyoshi, H.,
and Gores, G. J.
(2000)
Am. J. Physiol. Gastrointest. Liver Physiol.
278,
992-999
|
| 57.
|
Qiao, D.,
Stratagouleas, E. D.,
and Martinez, J. D.
(2000)
Carcinogenesis
22,
35-41
|
| 58.
|
Qiao, L.,
Studer, E.,
Leach, K.,
McKinstry, R.,
Gupta, S.,
Decker, R.,
Kukreja, R.,
Valerie, K.,
Nagarkatti, P., El,
Deiry, W.,
Molkentin, J.,
Schmidt-Ullrich, R.,
Fisher, P. B.,
Grant, S.,
Hylemon, P. B.,
and Dent, P.
(2001)
Mol. Biol. Cell
12,
2629-2645[Abstract/Free Full Text]
|
| 59.
|
Schliess, F.,
Kurz, A. K.,
von Dahl, S.,
and Haussinger, D.
(1997)
Gastroenterology
113,
1306-1314[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Kyriakis, J. M.,
and Avruch, J.
(2001)
Physiol. Rev.
81,
807-869[Abstract/Free Full Text]
|
| 61.
|
Tobiume, K.,
Matsuzawa, A.,
Takahashi, T.,
Nishitoh, H.,
Morita, K-I.,
Takeda, K.,
Minowa, O.,
Miyazono, K.,
Noda, T.,
and Ichijo, H.
(2001)
EMBO J.
21,
222-228[CrossRef]
|
| 62.
|
Saitoh, M.,
Nishitoh, H.,
Fujii, M.,
Takeda, K.,
Tobiume, K.,
Sawada, Y.,
Kawabata, M.,
Miyazono, K.,
and Ichiro, H.
(1998)
EMBO J.
17,
2596-2606[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Ichiro, H.,
Nishida, E.,
Irie, K.,
ten Dijke, P.,
Saitoh, M.,
Moriguchi, T.,
Takagi, M.,
Matsumoto, K.,
Miyazono, K.,
and Gotoh, Y.
(1997)
Science
275,
90-94[Abstract/Free Full Text]
|
| 64.
|
Go, Y. M.,
Levonen, A. L.,
Moellering, D.,
Ramachandran, A.,
Patel, R. P., Jo, H.,
and Darley-Usmar, V. M.
(2001)
Am. J. Physiol. Heart Circ. Physiol.
281,
2705-2713
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore